～With up to JPY 1.08 Billion in AMED Grant Support, Total Capital Associated with the Current Financing Exceeds JPY 1.6 Billion, Accelerating Clinical Development in Japan and North America～
Suita, Osaka, Japan — June 2, 2026 — Periotherapia Co., Ltd. (Headquarters: Suita, Osaka; President & CEO: Eiji Tahara; “Periotherapia”), a biopharmaceutical company spun out of The University of Osaka, today announced the first close of its Series D2 financing, pursuant to which the Company has raised JPY 575 million to date.
The first close consists of the issuance of J-KISS stock acquisition rights, a Japanese-style convertible equity instrument, to Mitsubishi UFJ Life Science No. 2 Investment Limited Partnership, for which Mitsubishi UFJ Capital Co., Ltd. serves as general partner, and Technoscience Co., Ltd., as well as debt financing from financial institutions.
This financing represents the initial closing of the Company’s Series D2 round, and the Company may continue discussions regarding potential subsequent closings.
In addition, Periotherapia has been selected to receive grant support of up to JPY 1.08 billion under the Japan Agency for Medical Research and Development (AMED)’s Drug Discovery Venture Ecosystem Enhancement Program. Including the proceeds from this first close and up to the maximum AMED grant support, the total capital associated with the current financing exceeds JPY 1.6 billion. Following this first close, the Company’s cumulative equity capital raised since inception exceeds JPY 2.4 billion.
Periotherapia is a spinout from The University of Osaka developing novel antibody therapeutics targeting pathological periostin, based on its vision of developing treatments for intractable diseases and delivering new medicines as quickly as possible to those in need.
The proceeds from this financing are intended to (i) advance the ongoing Phase 1/2a clinical trial in Japan and initiate a Phase 1/2a clinical trial in North America, (ii) expand the Company’s pipeline to support future growth, and (iii) strengthen its organizational structure and secure working capital to support continued clinical and business development.
Eiji Tahara, President & CEO of Periotherapia, commented:
“This first close will support the continued clinical development of our lead candidate, PT0101, for metastatic or recurrent HER2-negative breast cancer. Through these clinical efforts, we aim to demonstrate the potential of PT0101 to address treatment resistance by modulating the tumor microenvironment. Together with the AMED grant support, this financing marks an important step in advancing our clinical programs in Japan and North America. We view this financing as an important step toward our next stage of growth and will continue to drive development forward to create new treatment options for people living with serious and intractable diseases.”
Mikihiko Shinozaki, Deputy General Manager of Investment Department for Life Science, Mitsubishi UFJ Capital Co., Ltd., the lead investor in this first close, commented:
“We are pleased to have successfully reached this closing, thanks to the dedicated efforts of all parties involved. Since the Series A round, we have highly valued the potential of the antibody drugs targeting pathological periostin developed by Periotherapia and have continued to support its progress both financially and strategically as a committed partner.
Moving forward, while continuing to leverage the AMED grant, we will further reinforce our support for Periotherapia’s initiatives so that PT0101 can be delivered to patients suffering from cancer as quickly as possible.”
Going forward, Periotherapia will continue to advance its clinical programs in Japan and overseas, while also expanding its pipeline and strengthening its development capabilities. Pathological periostin, the Company’s therapeutic target, is a promising target in treatment-resistant breast cancer and other serious diseases where effective treatment options remain limited. Periotherapia has established a pioneering position in this field and remains committed to advancing its proprietary platform to create new therapeutic options for people living with serious and intractable diseases.
About Periotherapia Co., Ltd.
Periotherapia Co., Ltd. is a drug discovery startup founded in October 2017 by Dr. Yoshiaki Taniyama, a Director of the Company and Specially Appointed Professor in the Department of Advanced Molecular Therapeutics, Graduate School of Medicine, The University of Osaka. The Company has identified pathological periostin variants—aberrant forms of periostin, an extracellular matrix protein involved in heart valve formation and wound healing—as key drivers in a range of serious diseases, including breast cancer, diabetic retinopathy, and myocardial infarction. Periotherapia is developing antibody therapeutics targeting these pathological periostin variants.
Company Overview
Company Name: Periotherapia Co., Ltd.
Head Office: 2-8 Yamadaoka, Suita, Osaka, Japan
Representative: Eiji Tahara, President & CEO
Founded: October 2, 2017
Business: Research and development of antibody therapeutics
Website: https://periotherapia.co.jp/
Media Contact
Periotherapia Co., Ltd.
Takahiko Kawaguchi
E-mail: periotherapia@outlook.com
* The AMED grant amount refers to the maximum potential support amount under the program and is subject to applicable program terms and conditions, including matching investment requirements.